Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout


Clinical Trial Description

Phase Ib: single arm, open lable, single dose, dose escalation,design. There are 3 dose groups with 10 participant s in each group. Phase II: randomized, double-blind, active control design.There are 2 dose groups of Genakumab for Injection with 30 participant s in each group and 1 group of Compound Betamethasone Injection with 30 praticipants. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05983445
Study type Interventional
Source GeneScience Pharmaceuticals Co., Ltd.
Contact Ting Liu
Phone 18946532759
Email liuting01@gensci-china.com
Status Recruiting
Phase Phase 3
Start date January 15, 2023
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02674776 - Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout Phase 3
Not yet recruiting NCT05925166 - Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout N/A
Completed NCT00798369 - Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients Phase 2
Active, not recruiting NCT05328531 - Clinical Study of Genakumab for Injection in Patients With Acute Gout Phase 1/Phase 2
Completed NCT01080131 - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. Phase 3
Recruiting NCT05936268 - Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare Phase 2
Not yet recruiting NCT05936281 - Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy Phase 2
Recruiting NCT05588908 - A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout Phase 1/Phase 2
Recruiting NCT05698680 - Prednisolone Versus Colchicine for Acute Gout in Primary Care Phase 4
Completed NCT00142558 - A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) Phase 4
Not yet recruiting NCT06169891 - A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout Phase 3
Completed NCT01029652 - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study Phase 3
Withdrawn NCT00997581 - Apremilast Therapy for Acute Gouty Arthritis Phase 2